Skip to main content

Table 2 Estimates of concordance of serum values with clinical status of patients treated with trastuzumab

From: Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

Concordance

HER2/neu

CA15-3

Series testa

Cb

0.793

0.627

0.829

  1. aChange was considered positive if it was ≥ 15% for HER2/neu and ≥ 21% for CA15-3. bDifferences in concordance for HER2/neu and CA15-3 with 95%CI = 0.166 (lower limit 0.102, upper limit 0.227).
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us